Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19195144 | 0.85 | ALDH1A1 (0.68) | LMNAALDH1A1HTTMAPK1TP53 | |
| SCHEMBL17652438 | 0.85 | ALDH1A1 (0.68) | LMNAALDH1A1HTTMAPK1TP53 | |
| SCHEMBL17652439 | 0.85 | ALDH1A1 (0.68) | LMNAALDH1A1HTTMAPK1TP53 | |
| SCHEMBL22683206 | 0.83 | ALDH1A1 (0.66) | LMNAALDH1A1HTTMAPK1TP53 | |
| SCHEMBL19201600 | 0.83 | ALDH1A1 (0.66) | LMNAALDH1A1HTTMAPK1TP53 | |
| SCHEMBL28980625 | 0.83 | ALDH1A1 (0.65) | LMNAALDH1A1HTTMAPK1TP53 | |
| SCHEMBL20733397 | 0.83 | ALDH1A1 (0.65) | LMNAALDH1A1HTTMAPK1TP53 | |
| SCHEMBL9845673 | 0.83 | ALDH1A1 (0.65) | LMNAALDH1A1HTTMAPK1TP53 | |
| SCHEMBL19201599 | 0.83 | MAPT (0.67) | LMNAALDH1A1HTTMAPK1TP53 | |
| SCHEMBL12793407 | 0.80 | LMNA (1.00) | LMNAALDH1A1HTTMAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114617868-A | NRF2 activating compounds and uses thereof | 参宿七制药股份有限公司 | 2022-06-14 | — | — | CN | claimed |
| EP-3411361-A1 | NRF2 ACTIVATING COMPOUNDS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2018-12-12 | — | — | EP | claimed |
| WO-2017136589-A1 | NRF2 ACTIVATING COMPOUNDS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | claimed |
| CN-114617868-A | NRF2 activating compounds and uses thereof | 参宿七制药股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-108699011-B | NRF2 activating compounds and uses thereof | 参宿七制药股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3411361-B1 | NRF2 ACTIVATING COMPOUNDS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3411361-B1 | NRF2 ACTIVATING COMPOUNDS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3411361-A1 | NRF2 ACTIVATING COMPOUNDS AND USES THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| US-9845307-B2 | Nrf2 activating compounds and uses thereof | MIDCAP FINANCIAL TRUST | 2017-12-19 | — | — | US | disclosed |
| WO-2017136589-A1 | NRF2 ACTIVATING COMPOUNDS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017136589-A1 | NRF2 ACTIVATING COMPOUNDS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170217922-A1 | Nrf2 Activating Compounds and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217922-A1 | Nrf2 Activating Compounds and Uses Thereof | NFE2L2, KEAP1, NQO1 | LMNA 2725/4885ALDH1A1 1408/4885HTT 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.